Cancer Tech Accelerator ’s Post

The #biotech entrepreneurial journey can be equal parts frustrating, exhilarating, and rewarding. In the early stages, it's essential to keep an eye on scalability and lean on partners who can help you reach your next milestone quickly and cost-effectively. Our customers attest that RoosterBio can be a powerful resource for #advancedtherapy startups by providing: ✅ Scalable and economical raw materials to take you from bench to clinic ✅ Technical guidance along the way to optimize your chance of success ✅ Expert-led services to advance your research quickly and efficiently with reduced overhead cost Learn more: https://lnkd.in/eMGMeNV3 #advancedtherapies #regenerativemedicine #gotomarket #biotechinnovation #startup

💉 🔬 𝗣𝗮𝗿𝗶𝘀 - 𝗧𝗵𝗲 𝗙𝗼𝗿𝗲𝗳𝗿𝗼𝗻𝘁 𝗼𝗳 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 🔬 💉 Paris, traditionally the home of fashion, food & football, has now become a global hotspot for #biotech innovation. From leveraging its rich talent base in #scientificresearch research and #lifesciences to effect a #digital revolution in the medical field, #Paris is paving the way for the future of biotech Startups. The #startups listed here are infiltrating various areas of the vast biotech scene – from #genomics, #cellandgenetherapy, #precisiononcology, to #autoimmunetherapies with a mission to enhance the quality of human life. Below is highlighted 15 Paris domains startups that are making significant strides in the biotech industry, transforming it with their #innovative work, and revealing the potential of this vibrant city in leading the world in #biotechnology. Some of these innovative companies include! - One Biosciences: Focused on generating precision medicines by leveraging the power of #singlecell technologies CEO - Hedi Ben Brahim - Ermium Therapeutics:  specialization in developing creative therapies for auto-immune diseases CEO - Jean-Philippe Herbeuval - DeepLife: Using #AI to model cells and efficiently engineer their behavior. They aim at transforming #multiomics #data into #assets. CEO - Jean-Baptiste MORLOT - Mnemo Therapeutics: specialize in developing AcT-cell based #immunotherapies to treat #cancer patients CEO: Alain M. - Home Biosciences: A biotech company aiming to unlock scientific breakthrough by leveraging an asset-centric operating model CEO - David Schilansky & Magali RICHARD In conclusion, Parisian startups are decisively influencing the trajectory of the biotechnology sector. They are poised to lead Paris as the leading hub of scientific advancement through pioneering initiatives and cutting-edge technologies.

Our President, AI, Sona Chandra spoke with Maddyness UK about entrepreneurship and her advice for future founders, our working culture at Pangea, and how we are overcoming our biggest challenges to develop transformative therapeutics that can improve the quality of life and health outcomes for millions of patients. Thank you for the great feature! “[At Pangea]...we aim to blend the agility and speed of a tech startup with the rigorous, science-driven approach of a biotech company. This allows us to innovate rapidly while maintaining high scientific standards in our discovery pipeline, pushing the boundaries to develop groundbreaking therapies.” Here is the full article: https://lnkd.in/eTbviRVK #PangeaBio #DrugDiscovery #FemaleFounders #Startup #AI #DrugDevelopment #MedicinalPlants

#BiomedTech #Startups #Funding Biotech Funding Surge: Top Startups Raise $2.9B in Q1 2024” -Record Funding: The top 20 healthcare-focused biotech companies collectively raised $2.9 billion in Q1 2024, marking a 161% increase compared to the previous year. -Market Confidence: Investors are making more confident bets on the market viability of promising healthcare biotechnology firms. -Focus Areas: Funding recipients include companies specializing in precision oncology, AI-driven drug discovery, cell and gene therapies, and novel approaches to treating autoimmune disorders. Alumis Alumis (formerly Esker Therapeutics) secured $529M in cumulative funding, focusing on precision immunology and targeted treatments for autoimmune diseases. Freenome Freenome, a leader in early cancer detection, raised $1.35B in total funding for its multiomics screening platform. #BiotechFunding #HealthcareInnovation #PrecisionMedicine #HealthTech #LifeSciences #InvestmentNews #HealthcareStartups #InnovationFunding Ahmed-digital doc- Otokiti MD, MBA, MPH Alister Martin Philippe GERWILL Umer Khan M. Karim Beguir Harvey Castro, MD, MBA. Gabriella Marcelja

Biotech startups and spinouts often face significant hurdles as they move from the lab to the market. To address these challenges, we've established our Innovation Hub — a dedicated platform designed to de-risk and accelerate innovation in the biotech field. Our Innovation Hub serves as a nurturing ecosystem for early-stage biotechs, offering a comprehensive suite of tailored services to facilitate the journey from concept to commercialisation. This includes access to cutting-edge laboratory space and equipment, expert support and an extensive network of industry contacts to propel product development. Learn more about the barriers encountered by new Biotechs and how the Innovation Hub can help overcome them in our latest article in Chemistry World 👇 #Innovation #InnovationHub #Biotech #LifeSciences

The Next Biotech to Follow? Industry Booms with $20B+ Investment Over $20 billion invested in 2024 already, surpassing last year and signaling investor confidence in breakthrough treatments and cutting-edge tech like gene editing and antibody-drug conjugates. Major deals: BioAge: $170M ProfoundBio: $112M Areteia Therapeutics: $75M These investments highlight the booming interest in novel therapies across various diseases and innovative technologies. #biotech #innovation Full article 👉 https://lnkd.in/emutbyHy

Most drug discovery people tend to think that the effectiveness of their novel APIs is hampered by the lack of adequate drug targeting and precise delivery. Let's turn the conversation around to the question I usually ask.... Can new forms of drug delivery systems (DDS) enable new technological solutions and create therapies for patients in need, regardless of the novelty of API? Khosla Ventures Venture Capitalist Alex Morgan talks about their investment in. Cellfe - Compression wave cell transfection system Cellino- Parallel processing of cell therapies BioNaut - Magnetic guided device mini-device for minimally invasive brain delivery Liberate Bio - Bar-coded LNP formulation strategy for extra hepatic organ targeting. Nice portfolio.... ---- Disclaimer- Views expressed here are of the Author only https://lnkd.in/eH-VR26z

🚀 Biotech Industry Insights: Key Takeaways for 2024 🚀 Below, I have summarized some key take-home messages from Nature Magazine's article: "Biotech financing: darkest before the dawn" 1️⃣ Diverging Fortunes: While innovation thrives and M&A activity remains strong, the biotech sector is highly polarized. Established companies with proven assets attract significant investments, while early-stage biotechs struggle to secure funding. 2️⃣ Bigger, Fewer Rounds: Private funding rounds are more significant but less frequent, with a focus on clinical-stage assets. The average Series A rounds in the US now exceed $80M, double that of five years ago. 3️⃣ Hot Therapy Areas: Investment is flowing into obesity, neurology, and immunology. 4️⃣ Corporate VC Support: As traditional VCs face challenges, corporate venture capital is stepping up, particularly in Europe, supporting early-stage innovation. 5️⃣ Emerging Opportunities: AI and RLT (radioligand therapy) are attracting significant interest, with AI-driven startups like Xaira Therapeutics raising $1B in Series A funding. 6️⃣ Cautious Optimism: While public markets are tough, selected biotech IPOs are showing promise, and VC fundraising is recovering, with $20B in new biotech funds expected for 2024. 🔗 Bottom Line: Biotechs that align with big pharma needs and focus on hot therapeutic areas are poised for success. It's a challenging landscape, but opportunities abound for those on the right side of the innovation curve. #VentureCapital #Biotech #Innovation #Funding #LifeSciences

Discover some of the most promising Biotech startups making waves in the UK Industry right from Kent! Our newest blog post delves into the innovative work these companies are pioneering. Catch the full article here: https://lnkd.in/dpi_CDEC Featuring: Invictech Inc., a stellar company making strides in the Biopharma, Biotechnology and Medical industry. GenBody America, pushing the envelope in the Biotechnology, Health Diagnostics and Manufacturing industry. Humed Technologies, Inc., courageously developing cancer treatments and products for cancer patients, led by founders J. Zach Hilt, Joe Wyse, and Thomas Dziubla. Pangea Botanica, an exceptional establishment in the Bioinformatics, Biopharma and Biotechnology space founded by John Boghossian. Kanna Health, a preclinical stage company, creating novel therapeutics and headed by founder John Boghossian. Nodus Oncology, a promising startup focused on developing DDR targeting therapies. Join us in celebrating these trailblazing biotech startups! #Biotech #Startups #UKIndustry #Innovation #Biopharma #HealthDiagnostics #KentStartups

And... epigenetic editing holds hope, too. Continuing on the epigenetic thread: While the investment in biotech may have dropped the past year, it seems to be a reflection of a more measured approach rather than lack of excitement about the sector. And the excitement, among other things, seems to concentrate around epigenetic editing, bolstered by recent successes of cell and gene therapy overall: "Looking forward, the market analysts identified molecular glue degraders, epigenetic editing and macrocyclic peptides as three pockets of opportunity in 2024 and beyond." What were some of the recent successes in C&GT? FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease - https://lnkd.in/gVGVjryf Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia - https://lnkd.in/gYGjzGYG FDA Approves First One-time Cell Therapy for a Solid Tumor - https://lnkd.in/gZNRTXuv https://lnkd.in/gy_QV99K #cellandgenetherapy #epigenetics #epigeneticEditing